N-Terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], Aid Differentiation of E75-TCR(+)CD8(+) Cells to Perforin-positive Cells

Το τεκμήριο παρέχεται από τον φορέα :
National Technical University of Athens   

Αποθετήριο :
Digital Library of National Technical University of Athens | Dspace@NTUA   

δείτε την πρωτότυπη σελίδα τεκμηρίου
στον ιστότοπο του αποθετηρίου του φορέα για περισσότερες πληροφορίες και για να δείτε όλα τα ψηφιακά αρχεία του τεκμηρίου*



N-Terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], Aid Differentiation of E75-TCR(+)CD8(+) Cells to Perforin-positive Cells (EN)

Li, YF (EN)
Peoples, GE (EN)
Ioannides, CG (EN)
Tsuda, N (EN)
Fisk, B (EN)
Matsueda, S (EN)
Ishiyama, S (EN)
Ioannides, MG (EN)
Gao, H (EN)
Efferson, CL (EN)

journalArticle (EN)

2014-03-01T01:58:56Z
2009 (EN)


The objective of this study was to discover whether the peptides LRMK and LRMK-Ava linked to the N-terminus of peptides HER-2 (774-788) and HER-2 (776788), respectively, help differentiation of E75-TCR(+)CD8(+) cells. Activation was quantified in terms of proliferation of E75-TCR(+)CD8(+) cells expressing high, medium and low density amounts of the specific TCR. Differentiation to functional CD8(+) cells was quantified as induction of Perforin (Perf), the lytic-enzyme which mediates the effector function of CD8(+) cells, in E75-TCR(+)CD8(+) cells. Peripheral blood mononuclear cells (PBMCs) of 3 patients activated with E75(+)AE-37 and E75(+)AE-47 more greatly increased the number of E75-TCRHi CD8(+)Perf(+) cells than PBMCs activated by AE-47 alone or AE-47(+) E75. E75 plus cytokines and cytokines alone activated more E75-TCRLow cells than did AE-37 and AE-47. E75(+) AE-37 and AE-37 also induced differentiation of small- and medium-size activated CD8(+) cells from BRC ascites, in allogeneic activation, to Perf(+) cells. Preferential differentiation of E75-TCR(+)CD8(+)Perf(+) cells in distinct patients by AE-37 and AE-47 indicates that cancer vaccines will benefit from such correct individual and disease-associated help. Additional studies using the natural peptides p776 and F7 are needed to understand whether the LRMK-(Ava) tetra-, or pentamer augments or inhibits differentiation of CD8(+) cells, compared with native, natural HER-2 peptides and/or protects CD8(+) cells activated by E75 and by other HLA-I bound peptides from death. Our findings also develop a model for uniform quantification of differentiated CD8(+) effectors. (EN)

Oncology (EN)

high-affinity CD8(+) cells (EN)
helper effect (EN)
perforin (EN)
E75 (EN)
COMPLEX (EN)
CLINICAL-TRIAL (EN)
cancer vaccines (EN)
TUMOR (EN)
CLASS-II MOLECULES (EN)
INVARIANT CHAIN (EN)
HER-2 (EN)
F7 (EN)
RESPONSES (EN)
p776 (EN)
LYMPH-NODE (EN)
AE-47 (EN)
BREAST-CANCER PATIENTS (EN)
AE-37 (EN)
EPITOPES (EN)
VACCINES (EN)

ANTICANCER RESEARCH (EN)

Αγγλική γλώσσα

INT INST ANTICANCER RESEARCH (EN)




*Η εύρυθμη και αδιάλειπτη λειτουργία των διαδικτυακών διευθύνσεων των συλλογών (ψηφιακό αρχείο, καρτέλα τεκμηρίου στο αποθετήριο) είναι αποκλειστική ευθύνη των αντίστοιχων Φορέων περιεχομένου.